Related Experiment Video
Updated: May 24, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
[Drug-induced long QT syndrome. Relevancy in intensive care medicine]
R Laszlo1, S Laszlo, K Kettering
1Medizinische Klinik II (Kardiologie), Kreiskliniken Esslingen, Klinikum Kirchheim/Teck, Eugenstr. 3, 72320, Kirchheim/Teck, Deutschland. roman.laszlo@gmx.de
Abstract:
QT-prolonging drugs delay ventricular repolarization and, thus, favor the occurrence of Torsade de pointes (TdP). Intensive care patients are particularly endangered to suffer from this clinical picture as they often simultaneously exhibit multiple risk factors. In the following article, the most important risk factors for drug-induced long QT syndrome are described. An overview on how the QT interval can be influenced by various endo- and exogenous factors is provided. In addition, the measurement of this interval and potential sources of errors are described. Electrophysiological characteristics of TdP are delineated as well as important pathophysiological mechanisms of arrhythmogenesis, e.g., transmural dispersion of repolarization; T(peak)-T(end) interval as a marker for that dispersion is described. Potential explanations why prolongation of the QT interval is not the main or only factor for the proarrhythmic potential of QT-prolonging drugs are discussed. Furthermore, a summary of QT-prolonging drugs relevant in intensive care units is given and prevention of drug-induced long QT syndrome with consecutive TdP is discussed. Finally, recommendations for treatment of drug-induced TdP are reviewed.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug toxicity: Idiosyncratic Reactions